Exelixis Settles With Cipla To Resolve Two Patent Litigation; Grants Cipla License To Market Generic Versions Of CABOMETYX On Jan 1, 2031 If Approved By FDA And Subject To Conditions; Parties Terminate All Hatch-Waxman Litigation Regarding CABOMETYX